×

Cellular Biomedicine Group Calls for General Annual Stockholder Meeting on November 07, 2014

PALO ALTO, Calif., Oct. 7, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that the Board of the Company has set Friday, November 07, 2014 as the date for the Company's annual meeting of stockholders, to be held at the Company's office at 530 University Ave, Suite 17, Palo Alto, CA 94301, at 9:00am PST, and any and all adjournments or postponements thereof, and authorizes and instructs the designated proxies to vote in the manner directed in the proxy cards received for each stockholder of record.

A stockholder, once having received his/her proxy notice and access card, may view the proxy statement online or request a printed copy at www.iproxydirect.com/CBMG. Stockholders may vote online, by mail or by phone, according to the instructions on the proxy, no later than 11:59pm, Thursday, November 06, 2014, EST. Please send an email to sarah.kelly@CellBioMedGroup.com if you have questions about this proxy voting or have not received your proxy notice card in the mail.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com.

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 sarah.kelly@cellbiomedgroup.com Vivian Chen Managing Director Investor Relations, Grayling +1 646 284-9427 vivian.chen@grayling.com

Source:Cellular Biomedicine Group Inc.